Preclinical work indicates that calcitriol restores vascular function by normalizing the endothelial expression of cyclooxygenase-2 and thromboxane-prostanoid receptors in conditions of estrogen deficiency and thus prevents the thromboxane-prostanoid receptor activationinduced inhibition of nitric oxide synthase. Since endothelial dysfunction is a key factor in the pathogenesis of cardiovascular diseases, this finding may have an important translational impact. It provides a clear rationale to use endothelial function in clinical trials aiming to find the optimal dose of vitamin D for the prevention of cardiovascular events in postmenopausal women.
A recent, large epidemiological study with a median follow-up of 8.7 years showed that the lowest quartile of 25-hydroxyvitamin D (o17.8 ng/ml) was independently associated with all-cause mortality in the general population. A similar trend for increased cardiovascular mortality was observed in the lowest quartile, but the difference was not statistically significant. 1 However, in preselected sub-populations with an increased risk for cardiovascular diseases, including elderly people, 2 patients with preexisting systemic inflammatory diseases such as lupus nephritis, 3 and patients with suspected coronary heart disease, 4 vitamin D deficiency was clearly found to be associated with cardiovascular mortality. It is of note that the effects of vitamin D or calcitriol deficiency on cardiovascular morbidity and mortality seem to be long-lasting, but they also require a long time to become obvious. 5 We need to keep in mind that calcitriol deficiency might be dissociated from vitamin D deficiency, as vitamin D levels might be in the normal range but the conversion to calcitriol be impaired because of chronic kidney failure. Moreover, observations based on association studies such as the ones mentioned here [1] [2] [3] [4] [5] do not prove that correction of vitamin D deficiency or insufficiency will improve clinical outcomes. Definitive proof can be obtained only by doubleblind, placebo-controlled, adequately powered outcome trials.
Preclinical work in cell-culture systems and animal models helped in understanding the link between low vitamin D levels and cardiovascular disease. Vitamin D deficiency has been shown to be associated with enhanced synthesis and/or deleterious effects of many substances, including parathyroid hormone, various matrix metalloproteinases (MMPs), tumor necrosis factor-a, endothelium-derived contracting factors, and advanced glycation end products. Moreover, vitamin D deficiency also causes reduced synthesis of matrix Gla protein, osteopontin, and interleukin-10. The numerous alterations of the paracrine/endocrine system associated with vitamin D deficiency promote vascular calcification, 6 which is one of the possible pathways involved in cardiovascular morbidity and mortality. Another pathway is left ventricular hypertrophy and impaired cardiomyocyte contractility via reduced synthesis of MMP inhibitors in the face of enhanced MMP generation and decreased synthesis of cardiac muscle proteins. 6 Dong et al. 7 (this issue) report a novel molecular mechanism. In a very elegant study, they provide convincing evidence that renal artery cyclooxygenase-2 (COX-2) expression is elevated in rats with estrogen deficiency induced by ovariectomy, which in turn results in increased expression of thromboxane-prostanoid receptors. COX-2 products and thromboxaneprostanoid receptor activation reduce nitric oxide bioavailability, leading to impaired endothelium-dependent renovascular relaxation. Chronic calcitriol administration is shown to restore vascular function by normalizing the endothelial expression of COX-2 and thromboxane-prostanoid receptors, thereby preventing the reduction of nitric oxide generation that is induced by thromboxane-prostanoid receptor activation. Similar effects are obtained by acute exposure to three different COX-2 inhibitors and a thromboxaneprostanoid receptor antagonist, respectively. Moreover, exposure of renal arteries from ovariectomized rats to calcitriol also improves vascular relaxation and downregulates thromboxaneprostanoid receptor expression in short-term ex vivo experiments. Finally, the attenuated nitric oxide production in aortic endothelial cells from ovariectomized rats can be restored following short-term treatment with with calcitriol, a COX-2 inhibitor or a throboxane-prostanoid receptor antagonist. The study used renal arteries as a model system for arterial First, what is the optimal calcitriol dose to achieve this effect? A classical dose-response curve is missing.
Second, does native vitamin D have the same effect as calcitriol? Keeping in mind the well-known U-shaped vitamin D concentration-mortality curve seen in meta-analyses of association studies, 1 this question needs to be evaluated in the future.
Third, the long-term consequences of interfering with this newly described pathway for the structure and function of the kidneys and the cardiovascular system, including mortality, need to be carefully addressed in future animal experiments. It would also be good to replicate the above findings in a second, independent animal model. These would appear to be the first necessary steps in translating the findings described in the landmark study by Dong et al. 7 into clinical science.
Postmenopausal women represent a clinical subgroup with high cardiovascular risk. Hormone replacement therapy with estrogen, aimed to reduce the incidence of major cardiovascular adverse events, failed in this population. It actually was found to increase the risk, at least in women with preexisting cardiovascular disease. Pending additional work as suggested above (a proper dose-response curve, study with native vitamin D, and replication in an independent animal model), the pathway discovered by Dong et al. 7 could be explored in postmenopausal women, in whom one could examine the effect of optimal vitamin D supplementation in a phase 2 clinical trial before going to a large, costly phase 3 trial. Given the data provided by Dong and co-workers, 7 dose finding should be possible by the choice of endothelial function as a primary readout.
Hence, phase 2 trials with varying doses considering this readout should be used to find the optimal vitamin D dose for reducing cardiovascular events in postmenopausal women.
Without such an intermediary end point in phase 2 trials, moving directly to dose selection in a phase 3 trial resembles navigating in fog without radar. This happened in the past in interventional trials aiming to demonstrate beneficial cardiovascular effects. They were inconclusive most likely because of difficulties in finding the right dose and treatment duration for vitamin D. Figure 1 shows examples of past experience with controlled clinical trials in women and men aimed to reduce cardiovascular events with vitamin D.
In the context of the study by Dong et al. 7 it is important to note that in the large Women's Health Initiative study, a randomized controlled trial in 36,282 postmenopausal women aged 50-79 years at 40 clinical sites, the combined daily supplementation of calcium (1000 mg) and vitamin D (10 mg) did not alter the risk for coronary events or stroke. 8 Most likely, the dose of vitamin D was simply too low in this study. Moreover, the study tested two interventions at the same time without proper understanding of the clinical effects of calcium supplementation alone versus vitamin D supplementation alone. Most importantly, the authors did not use a reliable vitamin D dose-finding tool to explore the vitamin's effects on cardiovascular events in a phase 2 trial setting. They thus took the risk of navigating through fog without radar.
The beauty of the study by Dong et al. 7 -besides the discovery of a new pathway of vitamin D-related impairment of endothelial function under conditions of estrogen deficiency in female rats-is that it theoretically provides strong evidence for an end point for dose finding in clinical phase 2 vitamin D trials. Hopefully, this study will stimulate others to do more clinical work in an area of unmet medical need.
Measurement of ultrasound-based flow-mediated dilatation in the brachial codes for cardiovascular diseases 390.0-459.9, self-reported incidence or as cause of death from death certificate; 10 Brazier et al., myocardial infarction, pulmonary edema, and atrial fibrillation (including death from cardiovascular disease), estimated from reported data; 11 Hsia et al., nonfatal myocardial infarction or coronary heart disease death, from medical record review (events centrally adjudicated); 8 and Prince et al., ischemic heart disease, estimated from reported data. 12 c o m m e n t a r y artery in clinical studies is the current gold standard for analysis of endothelial dysfunction, as it is noninvasive, is relatively repeatable and reproducible, and reflects pathophysiology. Flowmediated dilatation seems to have cardiovascular-event predictability. Brachial artery endothelium-dependent dilatation is also significantly correlated with findings in the coronary circulation in the same patients. However, a number of new techniques have recently been proposed as potentially applicable screening tools for endothelial testing in humans, including pulse wave analysis, pulse wave velocity measurement, and pulse amplitude tonometry. Endothelial vasomotor function after reactive hyperemia by pulse amplitude tonometry, as measured in the fingertips, seems a very promising means of endothelial dysfunction analysis in humans.
In conclusion, the study by Dong et al. 7 describes a novel pathway demonstrating that calcitriol may correct endothelial dysfunction induced by estrogen deficiency. As endothelial dysfunction is a key factor in the pathogenesis of cardiovascular diseases, the study also has a translational impact. It provides a clear rationale to use endothelial function in clinical trials aiming to find the optimal dose of vitamin D for the prevention of cardiovascular events in postmenopausal women.
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